GleamWall
中文EN

HYFT MindWalk Holdings Corp. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1715925 · Reporting currency CAD · Fiscal year ends 04/30

Financial factors as of 2026-01-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY28.5%
TTM net income YoY73.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin60.3%
Operating margin—
Net margin-66.5%
FCF margin-64.8%
EBITDA margin—

Returns

ROE-61.5%
ROA-35.7%
ROIC (approx.)—
Asset turnover0.54x

Leverage & solvency

Liabilities / assets35.4%
Debt / equity0.00x
Current ratio3.74x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-3.1%
Payout ratio—
Capex / revenue4.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD 2026Q3*2026-01-312025Q2*2025-10-312025Q1*2025-07-312025Q4*2025-04-302025Q3*2025-01-312024Q2*2024-10-312024Q1*2024-07-312024Q4*2024-04-30
Income statement
Revenue4.16M4.12M3.16M6.98M2.73M2.68M2.47M6.46M
Cost of revenue1.69M1.46M1.63M2.52M967,0001.31M1.46M3.35M
Gross profit2.46M2.66M1.53M4.46M1.76M1.37M1.01M3.11M
R&D expense1.21M1.23M1.05M1.09M914,0001.01M1.49M927,000
SG&A expense3.12M3.07M3.29M3.71M2.86M2.85M3.35M4.12M
Pretax income-3.95M-3.19M-4.18M-1.90M-24.96M-4.28M-4.88M-18.82M
Income tax-18,00025,000-91,000261,000-3.01M-731,000-666,000-1.21M
Net income-3.93M-3.19M-2.96M-2.16M-21.52M-2.55M-4.00M-17.61M
EPS (basic)————-0.66-0.09-0.15—
EPS (diluted)————-0.66-0.09-0.15—
Balance sheet
Cash & equivalents14.20M16.64M5.02M10.79M13.01M3.62M4.00M3.54M
Inventory490,000531,000524,0002.10M1.92M2.01M1.87M2.14M
Current assets18.82M21.74M36.26M18.75M20.74M12.50M11.02M11.49M
PP&E, netmay include right-of-use assets (IFRS)4.02M4.21M4.34M15.76M15.22M15.96M16.44M16.70M
Goodwill0008.23M7.87M7.92M7.85M7.69M
Intangibles0001.07M1.12M23.01M23.42M23.56M
Total assets22.99M26.10M40.75M44.44M45.53M59.96M59.30M59.99M
Current liabilities5.03M5.19M16.69M9.01M8.93M12.41M11.17M8.12M
Total liabilities8.13M8.40M20.00M20.82M20.41M27.29M26.45M24.31M
Shareholders' equity14.86M17.71M20.74M23.63M24.95M31.89M32.84M35.68M
Shares outstanding——46.15M46.15M45.77M30.29M27.30M26.94M
Cash flow statement
Operating cash flow-2.97M-2.87M-4.21M-1.14M-1.20M-2.24M-1.82M-2.64M
Capital expenditure31,00074,000282,000359,000112,00065,000263,0001.13M
Free cash flow-3.00M-2.94M-4.50M-1.50M-1.31M-2.31M-2.09M-3.77M
Investing cash flow-12.89M-74,000-594,000-359,000-112,000-65,000-263,000-1.11M
Financing cash flow-13.31M14.08M-371,000-418,00010.55M2.07M2.70M1.12M
Depreciation & amortization217,000207,000942,000913,0001.40M1.42M1.40M1.58M
Stock-based compensation257,000153,00055,00053,00070,000176,000165,000237,000

Free plan shows the latest 8 periods; Pro shows all 14 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.